Aurobindo Pharma shares gain on U.S. FDA’s VAI classification of oral solid dosage unit

The Hindu online

www.thehindu.com

Generic drugmaker Aurobindo Pharma shares touched a new 52-week high on Wednesday (May 6, 2026) on the back of U.S. Food and Drug Administration (U.S. FDA) classifying a key manufacturing plant, it had inspected recently, as voluntary action indicated (VAI).The unit has now received Establishment In